Brooks Laboratories Ltd
NSE:BROOKS

Watchlist Manager
Brooks Laboratories Ltd Logo
Brooks Laboratories Ltd
NSE:BROOKS
Watchlist
Price: 62.46 INR -3.01% Market Closed
Market Cap: ₹1.8B

Net Margin

-0.4%
Current
Improving
by 21.1%
vs 3-y average of -21.5%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-0.4%
=
Net Income
₹-4.1m
/
Revenue
₹1.1B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-0.4%
=
Net Income
₹-4.1m
/
Revenue
₹1.1B

Peer Comparison

Country Company Market Cap Net
Margin
IN
Brooks Laboratories Ltd
NSE:BROOKS
1.9B INR
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.2T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
219.1B USD
Loading...
US
Danaher Corp
NYSE:DHR
156.8B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
82.4T KRW
Loading...
CH
Lonza Group AG
SIX:LONN
37.3B CHF
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
40.8B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
274.9B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
37.1B USD
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
28.6B USD
Loading...
US
Illumina Inc
NASDAQ:ILMN
22.6B USD
Loading...

Market Distribution

Lower than 82% of companies in India
Percentile
18th
Based on 5 531 companies
18th percentile
-0.4%
Low
-305 007.7% — 2.1%
Typical Range
2.1% — 11.6%
High
11.6% — 1 221 633.3%
Distribution Statistics
India
Min -305 007.7%
30th Percentile 2.1%
Median 5.8%
70th Percentile 11.6%
Max 1 221 633.3%

Brooks Laboratories Ltd
Glance View

Brooks Laboratories Ltd. is a research and development driven pharmaceutical manufacturing company. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2011-09-02. The firm operates through the Pharmaceuticals segment. The company manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup and eye/ear drops. Its products under Carbapenem category includes Imipenem 250mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 125mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, Doripenem 500mg and Doripenem 1000mg. The company offers Penicillins in the form of injections, tablets and dry syrup. Its General category of products include liquid injections, dry powder injections and eye/ear drops. The firm has two manufacturing plants, which are located at Baddi in Himachal Pradesh and Vadodara in Gujarat. The firm manufactures and markets the pharmaceuticals nationally and internationally to various regulated markets.

BROOKS Intrinsic Value
85.82 INR
Undervaluation 27%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-0.4%
=
Net Income
₹-4.1m
/
Revenue
₹1.1B
What is Brooks Laboratories Ltd's current Net Margin?

The current Net Margin for Brooks Laboratories Ltd is -0.4%, which is above its 3-year median of -21.5%.

How has Net Margin changed over time?

Over the last 3 years, Brooks Laboratories Ltd’s Net Margin has increased from -25.6% to -0.4%. During this period, it reached a low of -33.1% on Mar 31, 2023 and a high of -0.4% on Jun 30, 2025.

Back to Top